# Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma

> **NCT03777410** · — · TERMINATED · sponsor: **Travera Inc** · enrollment: 33 (actual)

## Conditions studied

- Multiple Myeloma in Relapse

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03777410
- **Lead sponsor:** Travera Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-11
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Insufficient pace of enrollment due to changes in MM SOC practices
- **Last updated:** 2024-07-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03777410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03777410, "Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple Myeloma". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT03777410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*